114 related articles for article (PubMed ID: 24567353)
1. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG
J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353
[TBL] [Abstract][Full Text] [Related]
2. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
3. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma.
Lin YL; Li ZG; Guan TY
Urol Int; 2013; 90(2):219-24. PubMed ID: 23171734
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.
Lin YL; Li ZG; He ZK; Guan TY; Ma JG
J Int Med Res; 2012; 40(6):2117-23. PubMed ID: 23321168
[TBL] [Abstract][Full Text] [Related]
9. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.
Lin YL; Ma JH; Luo XL; Guan TY; Li ZG
J Int Med Res; 2013 Feb; 41(1):48-54. PubMed ID: 23569129
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
12. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.
Uyen TN; Sakashita K; Al-Kzayer LF; Nakazawa Y; Kurata T; Koike K
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27643535
[TBL] [Abstract][Full Text] [Related]
18. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
Lin YL; Gui SL; Guo H; Ma JG; Li WP
Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.
Lin HH; Ke HL; Wu WJ; Lee YH; Chang LL
Urol Oncol; 2012; 30(2):177-81. PubMed ID: 20800513
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]